Veracyte (NASDAQ:VCYT) Price Target Raised to $49.00 at UBS Group
Veracyte (NASDAQ:VCYT – Free Report) had its price target increased by UBS Group from $46.00 to $49.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. VCYT has been the topic of several other reports. The Goldman Sachs Group reissued a “neutral” rating and issued […]
Veracyte (NASDAQ:VCYT – Free Report) had its price target increased by UBS Group from $46.00 to $49.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. VCYT has been the topic of several other reports. The Goldman Sachs Group reissued a “neutral” rating and issued […]
